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Background: Malaria is the major cause of morbidity and mortality in Angola. The most vulnerable groups to
Plasmodium falciparum infection are pregnant women and children under five years of age. The use of an
intermittent preventive treatment (IPT) with sulphadoxine/pyrimethamine (SP) in pregnant women was introduced
in Angola in 2006 by the National Malaria Control Programme, and currently this strategy has been considered to
be used for children malaria control. Considering the previous wide use of SP combination in Angola, together to
the reported cases of SP treatment failure it is crucial the evaluation of the prevalence of five mutations in pfdhfr
and pfdhps genes associated to P. falciparum resistance to SP before the introduction of S/P IPT in children.
Methods: The study was conducted in five provinces, with different transmission intensities: Huambo, Cabinda,
Uíge, Kwanza Norte, and Malanje. The detection of the mutations in pfdhfr and pfdhps genes was carried out in
452 P. falciparum blood samples by PCR RFLP.
Results: For pfdhfr gene, 90,3% of the samples carried the mutation 51I, with 7.5% of mixed infections; 51% carried
wild type allele 59C, with 29.2% mixed infections and; 99.1% of isolates harboured the mutant allele 108N.
Concerning, pfdhps gene, 83,1% were mutant type 437G with 11% mixed infections , while 87% of the studied
isolates were wild type for codon 540.
Discussion: This is the first representative epidemiological study of the whole Angola country on the prevalence
of the genotypes associated with SP chemoresistance. A high frequency of individual mutations in both genes
(51I and 108N in pfdhfr, and 437G in pfdhps) was found, besides a low prevalence of the quintuple mutation.
Conclusion: The data showed that the implementation IPT using SP in children needs to be reviewed.
Background
According to the Angolan National Malaria Control Pro-
gramme (NMCP), malaria is the major cause of morbid-
ity and mortality in Angola, with four million clinical
cases and 20 thousand deaths reported in 2005, account-
ing for 35% of the overall mortality in children under five
years old and 25% of the maternal deaths [1-3]. Malaria
is endemic throughout the Angolan territory, Plasmo-
dium falciparum being the predominant species [4]. Due
to the high prevalence of P. falciparum strains resistant
to chloroquine [5-8], therapeutic regimens for treatment
of uncomplicated P. falciparum infection were changed
in 2006 [9] and, currently, the first-line treatment for
uncomplicated malaria is Coartem
® (artemether-
lumefantrine) followed by the amodiaquine-artesunate
alternative therapy.
Additionally, in all Angolan endemic areas the strategy
to protect mothers during their pregnancy includes the
use of an intermittent preventive treatment (IPT)
[10,11]. This intervention has been introduced in Angola
since 2006, using sulphadoxine/pyrimethamine (SP) at
the second trimester of pregnancy.
In other African countries, SP - ITP has been also
introduced in children as a control measure to reduce
malaria morbidity and mortality in this most vulnerable
population [12] and has been evaluated in a number of
clinical trials in these countries, with success [12-17].
Thus, Angolan NMCP intends in the near future to
introduce this control measure in Angola. However, due
to the wide use of SP combination in this country
together to reported cases of SP treatment failure, it was
decided to obtain further information about SP resistance
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2007, before the introduction of such a control measure.
It is well known that mutations at the dihydropteroate
synthase (pfdhps) and dihydrofolate reductase (pfdhfr)
genes are associated with resistance of P. falciparum to
SP, respectively [18-21]. In pfdhfr, point mutations at
positions 51, 59, 108, and 164 are associated with pyri-
methamine resistance [22,23]. Similarly, mutations in
codons 437 (437G) and 540 (540E) of pfdhps are asso-
ciated with resistance to sulphadoxine [24-29].
Thus, to determine the polymorphism of pfdhps and
pfdhfr genes, infected blood samples were collected in
different representative endemic regions of the whole
country (Uíge, Kwanza Norte, Malanje, Cabinda and
Huambo) and the prevalence of five mutations of the
pfdhfr (N51I, C59R and S108N) and pfdhps (A437G and
K540E) genes was investigated.
Methods
Sample collection and DNA extraction
The blood samples used for this study were collected
originally as part of malaria surveillance activities of
NMCP. Community-based surveys were conducted in
five areas with different transmission intensity: Huambo,
Cabinda, Uíge, Kwanza Norte, and Malanje (Figure 1).
These samples were collected from asymptomatic
children under five years of age, at time of blood collec-
tion. Each sample consisted of 200 μlo ff i n g e r - p r i c k
blood spotted on filter papers, dried and stored at room
temperature until parasite DNA extraction.
Parent’s informed consent was obtained before inclu-
sion in the study, which was reviewed and approved by
the Ethical Committee from the Ministry of Health of
Angola. DNA was extracted from blood spotted on filter
paper, using phenol-chloroform method as described
elsewhere [30].
Analysis of mutations
Polymorphisms on the codons 51, 59, 108 in pfdhfr and
437, 540 in pfdhps were assessed by PCR RFLP after
amplification of DNA fragments by nested-PCR. The
PCR and enzymes restrictions reactions were carried out
under the conditions already described [31,32]. PCR
amplicons and digested fragments were separated on 2%
or 3% agarose gels stained with ethidium bromide and
visualized under UV.
Results
From one thousand and twelve samples collected in
five provinces from children that did not exhibit
malaria symptoms at the time of blood collection, 452
P. falciparum PCR positive samples were analysed in
Figure 1 Angola Map (adapted from http://www.rollbackmalaria.org/countryaction/angola_mis.html); the circles indicate the provinces
of study.
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Page 2 of 7this study: 208 (46%) were collected in Malanje, 96
(21%) in Kwanza Norte, 71 (16%) in Cabinda, 54 (12%)
in Uíge and 23 (5%) in Huambo provinces.
For pfdhfr gene, all 452 samples were successfully
characterized by PCR-RFLP for 51, 423 and 59 codons
and 430 samples for codon 108. Regarding pfdhps gene,
438 samples were characterized for codon 437 and 448
samples for codon 540. The analysis of pfdhfr showed
that 90,3% (408 out 452) of the isolates carried the
mutant allele 51I, while 7,5% (34 out 452) carried a
mixed infection (N and I); for 59 codon 51% (213 out
423) were wild type (C59), 29,2% (122 out 423) were
mixed infections (C and R) and 19,9% (83 out 423) car-
ried the mutant allele 59R.C o n c e r n i n gt h epfdhfr gene
codon 108, 99,1% (426 out 430) of isolates harbored the
mutant allele (N). For pfdhps 83,1% (364 out 438) were
mutant type (437G), 11% (48 out 438) were mixed
populations and 87% (390 out 448) of studied isolates
were wild type for codon 540 (K) (Table 1).
A mixture of infections with wild-type and mutant
alleles was also observed. These mixed infections were
seen for pfdhfr gene in positions 51 (34/452), 59 (122/
416) and 108 (1/430), and in pfdhps gene in positions
437 (45/438) and 540 (29/441). All mixed infections
were excluded from subsequent analysis. Therefore, suc-
cessful characterization of all five molecular markers
was obtained only in 241 samples out of a total of 452.
Only 25% (72) of the 400 isolates which were success-
fully characterized for the studied pfdhfr codons
harboured the triple pfdhfr 51-59-108 mutations and
one isolate carried the combination of three wild type
codons. The more frequent pfdhfr genotype was ICN,
which was found in 200 isolates (Table 2). Regarding
the pfdhps genotype GK, double mutation (437 and 540
codons) showed the highest frequency (91,1%). 225 iso-
lates harboured mutations on position 108 of pfdhfr
gene and 437 of pfdhps gene that were reported as the
initial mutations for pyrimethamine and sulphadoxine
resistance, respectively [23-36].
In pfdhfr gene, five mutant genotypes, NCN, NRN,
ICN, IRN and NCS (amino acids at positions 51, 59 and
108) were found confirming the major diversity of this
gene (Table 2). Among the studied isolates, 74% were
double mutants (ICN or NRN), most of them being type
ICN, and the triple mutant IRN was detected in 25% of
t h es a m p l e s .O n l yo n ei s o l a t ew a sas i n g l em u t a n t( ICS).
In pfdhps, three allele combinations GK, GE and AK
(amino acids at positions 437 and 540) were detected
nearly 3% being the double mutant GE and 91% of the
isolates were GK and 6% were wild-type (AK). Consider-
ing the two studied genes, 12 different genotype combi-
nations were found: NRN GK, ICN GK, IRN GK, IRN
GE, ICN AK, IRN AK, ICN GE, NCN AK, NRN AK,
ICS GK, NCN GK and NCS GK (51, 59 and 108 for
pfdhfr gene and 437 and 540 for pfdhps gene). From a
total of 241 isolates, 63% were ICN GK,2 5 %IRN GK,
3,7% were ICN AK, ICN GE. NRN GK and IRN AK
were detected with same frequency of the 1,7%, 1,2%
Table 1 Prevalence of mutations conferring resistance to SP in P. falciparum isolates from Angola
Prevalence of mutations in pfdhfr and pfdhps genes (%)
pfdhfr pfdhps
Province 51 59 108 437 540
Alleles n (%) n (%) n (%) n (%) n (%)
wild type 0 (0) 16 (27,6) 0 (0) 8 (12,1) 55 (83,3)
Cabinda mutant 70 (98,6) 28 (48,3) 64 (100) 57 (86,4) 3 (4,5)
mix infection 1 (1,4) 14 (24,1) 0 (0) 1 (1,5) 8 (12,1)
wild type 1(1,85) 19 (35,8) 0(0) 0 (0) 53 (98,1)
Uige mutant 52 (96,3) 15 (28,3) 50 (100) 52 (96,3) 1 (1,9)
mix infection 1 (1,85) 19 (35,8) 0 (0) 2 (3,7) 0 (0)
wild type 2 (2,1) 46 (49,5) 0 (0) 0 (0) 92 (95,8)
Kwanza Norte mutant 91 (94,8) 25 (26,9) 92 (100) 93 (96,9) 2 (2,1)
mix infection 3 (3,1) 22 (23,7) 0 (0) 3 (3,1) 2 (2,1)
wild type 7 (3,4) 127 (62,6) 3 (1,5) 16 (7,7) 189 (90,9)
Malanje mutant 173 (83,2) 12 (5,9) 199 (98) 156 (75) 5 (2,4)
mix infection 28 (13,5) 64 (31,5) 1 (0,5) 34 (16,3) 13 (6,3)
wild type 0 (0) 5 (45,5) 0 (0) 2 (12,5) 11 (61,1)
Huambo mutant 22 (95,7) 3 (27,3) 21 (100) 6 (37,5) 1 (5,6)
mix infection 1 (4,4) 3 (27,3) 0 (0) 8 (50) 6 (33,3)
wild type 10 (2,2) 213 (51,0) 3 (0,7) 26 (5,9) 390 (87,1)
Total mutant 408 (90,3) 83 (19,9) 426 (99,1) 364 (83,1) 29 (6,5)
mix infection 34 (7,5) 122 (29,2) 1 (0,2) 48 (11,0) 29 (6,5)
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Page 3 of 7were NRN GK and ICN GE, all other combinations were
found with a very low frequency (Table 2).
In a comparison evaluation between provinces, the
same pattern was found except for Cabinda, where the
most frequent genotype was IRN (Tables 1 and 2).This
province is geographically separated from the rest of the
country.
Discussion
The monitoring of SP resistance is relevant in order to
guide national malaria treatment policies before intro-
duction of SP as IPT in children at Angola. In this light,
this study was designed to assess the pfdhfr and pfdhps
mutations associated with SP chemoresistance. For this
purpose, the mutations at pfdhfr (N51I, C59R and
S108N)a n dpfdhps (A437G and K540E) genes, consid-
ered predictive of SP treatment failure [25-27], were
assessed in five provinces of Angola. Four of them -
Uíge, Kwanza Norte, Malanje and Cabinda - are hyper-
endemic areas, whereas Huambo, is a mesoendemic
stable. It this way, it was observed the presence of the
mutations 51I and 59R jointly with 108N,w h i c h
enhances the level of resistance to pyrimethamine when
compared with single mutation in codon 108 [35-37].
Similarly, mutations in 437 (437G) and 540 (540E)
pfdhps codons are associated with resistance to sulpha-
doxine [24-29]. In pfdhfr gene, the mutation at position
108 (S108N), which is believed to be the initial mutation
causing pyrimethamine resistance, was observed in
almost all isolates successfully characterized for this
codon (426/430) (Table 1). In pfdhps gene, among the
438 characterized isolates, 364 presented the mutant
allele at position 437, which has been reported as the
initial mutation for sulphadoxine resistance in many
endemic regions.
From 430 P. falciparum isolates characterized in this
study, 99,1% carried the pfdhfr 108N mutation. The
results also showed that 27% of P. falciparum isolates
presented double mutations at codons 59 and 108, indi-
cating the development of resistance against antifolates
in Angola. Another double mutant (51I 108N)w a s
observed in 96,7% of Angolan P. falciparum isolates;
these results were consistent with the results obtained in
a similar study carried out at Uíge province in 2009 [38].
A 25% of pfdhfr triple mutant prevalence (51I/59R/
108N) was also noticed. The prevalence of these
Table 2 Prevalence of haplotypes in P. falciparum isolates from Angola
Genotypes Cabinda Uige Kwanza Norte Malanje Huambo Total
n (%) n (%) n (%) n (%) n (%) n (%)
51 59 108
IRN 28 63,6 13 40,6 22 32,4 5 3,9 1 16,7 69 24,8
ICN 16 36,4 18 56,3 44 64,7 117 91,4 5 83,3 200 71,9
pfdhfr ICS 0,0 0,0 0,0 1 0,8 0,0 1 0,4
NCN 0,0 0,0 0,0 2 1,6 0,0 2 0,7
NRN 0,0 1 3,1 2 2,9 3 2,3 0,0 6 2,2
n 44 32 68 128 6 278
437 540
GK 50 87,7 51 98,1 89 94,7 144 89,4 5 62,5 339 91,1
pfdhps GE 3 5,3 1 1,9 2 2,1 5 3,1 1 12,5 12 3,2
AK 4 7,0 0 0,0 3 3,2 12 7,5 2 25,0 21 5,6
n 57 52 94 161 8 372
51 59 108/437 540
ICN/GK 10 27,8 17 54,8 41 60,3 83 81,4 1 25,0 152 63,1
IRN/GK 22 61,1 14 45,2 20 29,4 4 3,9 1 25,0 61 25,3
IRN/AK 2 5,6 0,0 2 2,9 0,0 0,0 4 1,7
ICN/AK 0,0 0,0 1 1,5 6 5,9 2 50,0 9 3,7
NRN/GK 0,0 0,0 2 2,9 1 1,0 0,0 3 1,2
pfdhfr/pfdhps ICN/GE 1 2,8 0,0 2 2,9 0,0 0,0 3 1,2
ICS/GK 0,0 0,0 0,0 1 1,0 0,0 1 0,4
ICN/GE 0,0 0,0 0,0 4 3,9 0,0 4 1,7
NCN/GK 0,0 0,0 0,0 1 1,0 0,0 1 0,4
NRN/AK 0,0 0,0 0,0 1 1,0 0,0 1 0,4
NCN/AK 0,0 0,0 0,0 1 1,0 0,0 1 0,4
IRN/GE 1 2,8 0,0 0,0 0,0 0,0 1 0,4
n 36 31 68 102 4 241
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tion at position 437G in pfdhps (83,1%) may indicate
that these P. falciparum parasite populations have the
potential to evolve into pfdhfr/pfdhps quintuple mutant
in the near future, a mutant that is considered a mole-
cular marker of SP treatment failure [25-27].
In addition, the simultaneously presence of 59R pfdhfr
and 540E pfdhps variants is considered predictive of the
presence of quintuple mutant (pfdhfr 51I,5 9 R,1 0 8 N,
pfdhps 437G, 540E) [25-40]. In fact, despite high frequen-
cies of mutations in this report, only one isolate was found
harbouring the quintuple mutant associated with high
level of resistance to SP. This finding is in accordance with
the results obtained in other similar studies carried out in
Angola, Republic of Congo and Gabon [31,28,29].
The predominant pfdhfr haplotype in the present work
was 51I59C108N (71,9%), corroborating the results
reported with Brazilian samples by Gama and collabora-
tors [41]. The triple mutant 51I59R108N (24,8%) was of
low prevalence in the examined isolates, similarly to
previous data reported in Sri Lanka [42] and Papua New
Guinea [43], but different from the isolates from Malay-
sia [44], Brazil [45] and India [46] where this triple
mutant was the predominant haplotype. In Africa, the
Republic of Congo [28] and Gabon [29] also shows dif-
ferences when compared with these Angolan data,
except in the province of Cabinda. The differences
found between Cabinda isolates and the rest of studied
isolates may be due to geographical location of this pro-
vince and its proximity to the neighboring countries
Gabon and Congo and the movement of people between
these regions. Most of the P. falciparum isolates (91,1%)
revealed the haplotype 437G540K for pfdhps gene with
low prevalence of mutation at codon 540 (3,2%).
The triple pfdhfr/pfdhps (59R108N/437G)m u t a n t
haplotype was found in 27% of isolates, the 51I108N/
437G was the mutant haplotype more prevalent in stu-
died isolates.
The results obtained in the present study are in line
with those obtained with Iranian isolates where 51I
mutation seems be a good molecular marker for the tri-
ple mutant pfdhfr/pfdhps [47]. By the other hand, theses
results seem to be in contrast with the data obtained in a
study carried out in Mozambique which claimed that the
mutations at codon 59 in pfdhfr and codon 437 in pfdhps
were enough to predict SP treatment failure [48], as well
as in Burkina Faso [49] where the results showed that
pfdhfr 59R is more relevant than the 51I as a marker of
SP treatment failure.
Finally, this is the first molecular study carried out in
Angola including a large number of samples (452) from
five different provinces of the country, and where five
mutations of pfdhps and pfdhfr genes, predictive of SP
therapeutic failure were screening showing high
frequencies of 51I, 108N pfdhfr alleles, and 437G of
pfdhps gene with an almost absence of the quintuple
mutation for SP.
Conclusion
The high frequencies of mutations and haplotypes
linked to antimalarial treatment failure (for example the
88% frequency of isolates carrying pfdhfr 51I108N -
pfdhps 437G triple mutant allele, critical to SP resis-
tance) herein described, highlight the need to revaluate
the strategy of SP introduction as an IPT in children as
well as the current use of SP for pregnant women IPT
purposes, in Angola.
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